image

Healthcare Market Report Scope & Overview:

The Healthcare Market size was estimated USD 21222.52 billion in 2023 and is expected to reach USD 41670.45 billion by 2031 at a CAGR of 8.8% during the forecast period of 2024-2031.

Health Care Market refers to people, businesses, and organizations that offer healthcare services. In the Health Care Market, Mindscape shall only have the restricted, nonexclusive right to retail direct marketing with respect to people who are engaged in the provision of health care services, notwithstanding anything herein to the contrary. With regard to businesses and institutions that offer healthcare services, Mindscape shall not be permitted to engage in retail direct marketing in the health care sector.

Healthcare Market Revenue Analysis

MARKET DYNAMICS

DRIVERS

  • Aging population

The population is the main factor influencing the expansion of healthcare. The healthcare sector as a whole will experience an increase in demand for medical services as the sizable baby-boom population ages and people continue to be active into their older years. In all facets of the sector, managers will be required to coordinate and oversee the healthcare and medical information staffs.

  • Advancing Technology

The way healthcare is delivered and managed will continue to alter as a result of new technology. Information systems, recordkeeping, healthcare, and information exchange will all continue to develop and grow more complex. The potential for businesses to diversify their healthcare solutions will probably increase with new technology. There may also be a demand for technical healthcare managers who can plan, direct, and integrate new technological solutions into existing organizations as a result of developments in medical technology and information systems.

RESTRAIN

  • Expensive implementation

It takes a lot of research and development to create and improve BMP medications. It takes time and money to comprehend the mechanism of action, improve formulations, and carry out preclinical and clinical trials. Costly resources are needed to fund research teams engaged in such R&D operations, conduct tests, and purchase materials and equipment. In addition, the significant cost of BMP market implementation may provide difficulties for healthcare providers, insurers, and patients. BMP therapies may not be affordable for persons with little financial resources or insufficient access to healthcare due to their expensive prices, which will restrict market growth.

OPPORTUNITY

  • Increasing pharmaceutical market key players

Over the next five years, there will likely be abundant growth prospects for the healthcare facilities management market in the United States due to the rising number of market participants and the high availability of cutting-edge cloud-based healthcare facility management systems. The adoption of remote monitoring medical devices is anticipated to be accelerated by the widespread use of the internet and the growth of intelligent devices. Patients are becoming more knowledgeable about the benefits of employing cutting-edge tools and technology that are more precise and efficient than conventional medical instruments.

  • Independent medical facilities

Before the epidemic, these hospitals were already well on their way to become enduring pillars of our country's healthcare system. However, they may now provide smaller and better-controlled conditions to conduct what they do without the increased exposure that truly causes a pandemic, in addition to their frequently cheaper cost, enhanced efficiency, and comforts. These facilities were already a wise investment, and the patient mentality that cautions against exposure to huge infectious pools like hospitals will only help them further.

  • Telehealth

Before the pandemic, telehealth was not seen as "really" practicing medicine. And to make matters worse, numerous regulatory bodies and third-party payers even had fraud suspicions. State medical boards got to work disenfranchising it from the practice of medicine. Then Covid-19 occurred, and all of a sudden, patients were not even allowed to visit their doctors. People were connected digitally because need is the mother of invention. With the capacity to even incorporate vital signs into e-visits, home health medical equipment helped with the changeover. Telehealth was probably going to happen sooner or later because progress in capitalism is when more is accomplished with less money spent. By a full generation, Covid-19 has just accelerated its respectability. These businesses are currently just emerging from their early-stage difficulties; they are here to stay and will be extremely successful.

CHALLENGES

  • Increasing Healthcare Costs

The rising cost of healthcare has a direct influence on the revenue of healthcare organizations because patients are deterred from completing routine follow-ups after visits and taking lab tests as a result of higher costs, which eventually results in poor patient outcomes.

  • Shortages of Healthcare Personnel

Staffing shortages in the healthcare sector are a serious challenge that have been made worse by the COVID-19 epidemic. In the upcoming years, it is anticipated that demand for healthcare workers, such as doctors and registered nurses (RNs), would outpace supply. By 2030, industry associations foresee a shortage of almost 100,000 doctors, while the Bureau of Labor Statistics projects a need for 203,700 new RNs year through 2026.

IMPACT OF RUSSIAN UKRAINE WAR

The World Medical Association Declaration on the safety of Healthcare Workers has been flagrantly violated by Russia's attacks on healthcare facilities. The WHO reported on August 9, 2022, that more than 432 times had been assaulted by Russian armed troops (366 times on medical facilities and 72 times on medical personnel, resulting in fatalities and serious injuries). Supply chain problems and immunization administration errors, which result in significantly decreased vaccine coverage, are the main causes of healthcare disruption. Destroying medicinal and vaccine materials results in diminished supplies, which has an impact on the chain of storage and transportation. Because of this, a large portion of the population is more susceptible to severe illnesses, which can cause epidemics. Delays in polio and measles vaccinations can result in the majority of catastrophic outcomes in youngsters. Additionally, inadequate sanitation and a lack of a safe water supply might contribute to the development of infections. Due to a lack of amenities and medical assistance, the female population is negatively impacted.

Moreover, because Ukraine has a well-established centralized healthcare system that aids numerous pharmaceutical companies in easy and quicker recruitment, Ukraine has been one of the top locations for conducting clinical trials. Additionally, Ukraine has a sizable patient population that is treatment naive and GCP compliant staff and infrastructure. The prolonged battle is causing a number of issues, including the inability to recruit new patients for clinical studies and the blockage of the supply chain, which will and already has had an impact on the pharmaceutical business.

IMPACT OF ECONOMIC SLOWDOWN

Recession could cut healthcare sector profits by more than $70 billion in 2023. While many factors will contribute to this recession, here are some of the most prominent challenges such as supply chain disruptions- providers are being forced by price demands for specialty medical supplies to bargain with unreliable suppliers and handle international shipping constraints. As a result, medical supply prices grew by 46% last year, outpacing labor expense growth.  The rising energy costs-the War in Ukraine has led to higher transportation rates that suppliers are now passing on to providers.  Doctors and nurses are still in short supply due to labor shortages. Healthcare employment has decreased by 1.1% (or 176,000) during the pre-pandemic period, remaining below pre-pandemic levels. 

KEY SEGMENTS

  • Pharmaceuticals, by Type

    • Production and distribution of prescription

    • Over-the-counter drug

    • Biologics

    • Others

  • Healthcare Services, by Types

    • Hospitals

    • Clinics

    • Nursing homes

    • Other facilities that provide medical care to patients

  • Medical Devices, by Types

    • MRI machines

    • Pacemakers

    • Surgical instruments

    • Diagnostic equipment

    • Others

  • Biotechnology, by Types

    • Development of new drugs

    • Therapies

    • Medical technologies

    • Others

  • Pharmacy and Retail, by Types

    • Pharmacies

    • Drugstores

    • Retail outlets

    • Others

  • Home Healthcare, by Types

    • Home nursing

    • Medical equipment

    • In-home monitoring

    • Others

  • Diagnostics, by Types

    • Medical imaging

    • Blood tests

    • Genetic testing

    • Others

  • Health and Wellness, by Types

    • Fitness

    • Nutrition

    • Wellness products and services

Healthcare Market Segmentation Analysis

REGIONAL ANALYSES

North America held a significant market revenue share of 43% in 2023 due to high costs is healthcare companies’ adoption of emerging health-focused technology. Healthcare facilities and providers in the US will spend $29.15 billion on cloud-based technology by 2026, up from $17.9 billion in 2022. Also, Big data is being used more frequently, and there are more government regulations and support for healthcare IT solutions. Moreover, the demand for healthcare services is rising across North America as a result of rising health insurance rates, a rise in the number of elderly persons, and an increase in the prevalence of chronic diseases. Patient readmissions, medical errors, and administrative costs are a few more aspects of the high cost of healthcare services.

Asia Pacific is witnessing to expand the fastest CAGR rate during the forecast period. Due to continued improvements in healthcare and the adoption of prescriptive and predictive analytics technologies by the majority of regional hospitals, Japan is anticipated to become one of the key regional drivers. The sizeable senior patient population and rising healthcare costs would further help Japan's market dominance in healthcare analytics.

REGIONAL COVERAGE

North America

  • US

  • Canada

  • Mexico

Europe

  • Eastern Europe

    • Poland

    • Romania

    • Hungary

    • Turkey

    • Rest of Eastern Europe

  • Western Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Netherlands

    • Switzerland

    • Austria

    • Rest of Western Europe

Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Vietnam

  • Singapore

  • Australia

  • Rest of Asia Pacific

Middle East & Africa

  • Middle East

    • UAE

    • Egypt

    • Saudi Arabia

    • Qatar

    • Rest of Middle East

  • Africa

    • Nigeria

    • South Africa

    • Rest of Africa

Latin America

  • Brazil

  • Argentina

  • Colombia

  • Rest of Latin America

Key Players

Key Players by Pharmaceuticals – Pfizer, Novartis, Merck & Co., Roche, GSK, Sanofi, Johnson & Johnson, AstraZeneca, AbbVie, and Others.

Key Players by Healthcare Services - UnitedHealth Group, Medtronic plc, GE HealthCare, McKesson, Abbott Laboratories, Johnson & Johnson, Philips, Pfizer, CVS Health Payor Solutions, and Others.

Key Players by Medical Devices- Abbott, Medtronic, Johnson & Johnson, Siemens Healthineers, Fresenius Medical Care, Becton Dickinson & Company, GE Healthcare, Stryker, Philips, Cardinal Health, and Others.

Key Players by Biotechnology- Eli Lilly 1LLY, Novo Nordisk 2NVO, Johnson & Johnson, Merck, AbbVie, Roche, AstraZeneca, Novartis, Thermo Fisher Scientific, Amgen, and Others.

Key Players by Pharmacy and Retail- Cardinal Health, Inc, Wal-Mart Stores, Inc., McKesson Corporation, CVS Health Corporation, Walgreens Boots Alliance, and Others.

Key Players by Diagnostics- Thermo Fisher Scientific, IDEXX Laboratories, SGS, Quest Diagnostics, Revvity, Exact Sciences, bioMérieux, Eurofins Scientific, Bruker, Sonic Healthcare, and Others.

Key Players by Health and Wellness- Amway Corporation, Bayer AG, Danone S.A., David Lloyd Leisure Ltd., Curefit Healthcare Pvt. Ltd., Herbalife International of America, Inc., Letterone Investment Holdings S.A., L’Oreal S.A., Nestle S.A., The Procter & Gamble Company, and Others.

Johnson & Johnson-Company Financial Analysis

Company Landscape Analysis

RECENT DEVELOPMENT

In October 2023, according to an official release, Palivizumab, a critical preventive treatment for Respiratory Syncytial Virus (RSV), has gained marketing permission from the Central Drugs Standard Control Organization (CDSCO) to be imported and marketed in India by AstraZeneca Pharma Ltd.

In August 2023, Roche Pharma India inaugurated a customer experience center in Chennai. The pharmaceutical company asserts that it is an industry-first program that intends to foster collaboration between researchers, educators, and healthcare professionals in order to help influence the future of healthcare.

In February 2023, With the launch of its new product, "Ocular Defense," Herbalife Nutrition India announced that it had entered the eye health market. The medicine is said to be designed scientifically to support eye health and is available in capsule form, according to the manufacturer. According to its claims, the product provides nutrients that support macular health and maintain normal eyesight.

USE CASES:

Artificial intelligence in healthcare has several important applications, including medical imaging. AI algorithms' precision in analyzing medical pictures, such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and X-rays, gives healthcare providers invaluable information about the situations of their patients. With the use of this technology, diagnoses may be made more quickly and accurately, which benefits patients. Here are a few specific instances of AI's use in medical imaging.

Medical experts can identify and treat ailments using AI's analysis of medical imagery. For instance, AI systems can help with surgery planning by analyzing MRI data to detect brain tumors. By examining brain scans and detecting any changes in the brain's volume and structure, it can also assist in the early detection of dementia and Alzheimer's disease. AI may also examine retinal scans to find early-stage diabetic retinopathy, a condition that diabetic individuals may develop that can result in blindness.

Challenges:

  • Healthcare organizations are still catching up with the huge backlog of imaging-related needs in the post-pandemic world.

  • Healthcare providers are finding it challenging to meet the demand for imaging services as the number of elderly patients rises.

  • The demand for AI-based clinical decision support is increasing as a result of inaccurate or missing diagnoses brought on by human mistake or subjective interpretations.

  • There is unquestionably a need for faster and more effective imaging analysis and reporting.

Key Objectives:

  • Better image capture (Image capturing devices (MRI, X-ray, ultrasound, etc), noise

  • removal during capture, enhanced resolution or contrast, image compression, databases, etc.)

  • Better image processing (diagnostics, object identification, object segmentation, search, etc)

  • Improved image display (3D viewing, volumetric display, generating 3D from 2D slices, etc)

Conclusion

AI-powered medical imaging is revolutionizing the healthcare industry by giving patients access to more precise, effective, and individualized diagnosis and treatment options. Artificial intelligence (AI) technology is assisting medical practitioners in identifying anomalies that were previously missed by conventional imaging techniques, such as cardiovascular disorders, fractures, and musculoskeletal injuries. AI technology is positioned to disrupt the healthcare sector by enhancing patient care and results as the need for medical imaging keeps rising.

Healthcare Market Report Scope:
Report Attributes Details

Market Size in 2023

 US$ 21222.52 billion      

Market Size by 2031

 US$ 41670.45 billion   

CAGR 

 CAGR of 8.8% From 2024 to 2031

Base Year

2023

Forecast Period

 2024-2031

Historical Data

 2020-2022

Report Scope & Coverage

Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook

Key Segments

Healthcare Market Size, Share and Segmentation, By Pharmaceuticals, By Healthcare Services, By Medical Devices, By Biotechnology, By Pharmacy and Retail, By Home Healthcare, By Diagnostics, By Health and Wellness.

Regional Analysis/Coverage

North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America)

Market Opportunities

• Increasing pharmaceutical market key players                                                                                                • Independent medical facilities                                                                         

Market Challenges

•Increasing Healthcare Costs                                                                                                                      •Shortages of Healthcare Personnel

 

Frequently Asked Questions

Healthcare Market forecast period is  2024 to 2031.

The growth rate of Healthcare Market is expected to grow USD 41670.45 billion by 2031.

Healthcare Market size was valued at USD 21222.52 billion in 2023.

A growing wave of aging demographics and a constant wave of new technologies that are transforming how healthcare is delivered and managed.

Healthcare Market is anticipated to expand by 8.8% from 2024 to 2031.

Table of Content

1. Introduction

1.1 Market Definition
1.2 Scope
1.3 Research Assumptions

2. Research Methodology

3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges

4. Impact Analysis

4.1 Impact of the Russia-Ukraine war
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World

5. Value Chain Analysis

6. Porter’s 5 forces model

7. PEST Analysis

8. Global Healthcare Market Segmentation, By Type
8.1 Pharmaceuticals, By Type
8.1.1 Production and distribution of prescription
8.1.2 Over-the-counter drugs
8.1.3 Biologics
8.1.4 Others
8.2 Healthcare Services, By Type
8.2.1 Hospitals
8.2.2 Clinics
8.2.3 Nursing homes
8.2.4 Other facilities that provide medical care to patients
8.3 Medical Devices, By Type
8.3.1 MRI machines
8.3.2 Pacemakers
8.3.3 Surgical instruments
8.3.4 Diagnostic equipment
8.3.5 Others
8.4 Biotechnology, By Type
8.4.1 Development of new drugs
8.4.2 Therapies
8.4.3 Medical technologies
8.4.4 Others
8.5 Pharmacy and Retail, By Type
8.5.1 Pharmacies
8.5.2 Drugstores
8.5.3 Retail outlets
8.5.4 Others
8.6 Home Healthcare, By Type
8.6.1 Home nursing
8.6.2 Medical equipment
8.6.3 In-home monitoring
8.6.4 Others
8.7 Diagnostics, By Type
8.7.1 Medical imaging
8.7.2 Blood tests
8.7.3 Genetic testing
8.7.4 Others
8.8.1 Health and Wellness, By Type
8.8.1 Fitness
8.8.2 Nutrition
8.8.3 Wellness products and services

9. Regional Analysis
9.1 Introduction
9.2 North America
9.2.1 North America Chemical Market, By Country
9.2.2 North America Chemical Market, By Pharmaceuticals
9.2.3 North America Chemical Market, By Healthcare Services
9.2.4 North America Chemical Market, By Medical Devices
9.2.5 North America Chemical Market, By Biotechnology
9.2.6 North America Chemical Market, By Pharmacy and Retail
9.2.7 North America Chemical Market, By Home Healthcare
9.2.8 North America Chemical Market, By Diagnostics
9.2.9 North America Chemical Market, By Health and Wellness
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Eastern Europe Chemical Market, By Country
9.3.1.2 Eastern Europe Chemical Market, By Pharmaceuticals
9.3.1.3 Eastern Europe Chemical Market, By Healthcare Services
9.3.1.4 Eastern Europe Chemical Market, By Medical Devices
9.3.1.5 Eastern Europe Chemical Market, By Biotechnology
9.3.1.6 Eastern Europe Chemical Market, By Pharmacy and Retail
9.3.1.7 Eastern Europe Chemical Market, By Home Healthcare
9.3.1.8 Eastern Europe Chemical Market, By Diagnostics
9.3.1.9 Eastern Europe Chemical Market, By Health and Wellness
9.3.2 Western Europe
9.3.2.1 Western Europe Chemical Market, By Country
9.3.2.2 Western Europe Chemical Market, By Pharmaceuticals
9.3.2.3 Western Europe Chemical Market, By Healthcare Services
9.3.2.4 Western Europe Chemical Market, By Medical Devices
9.3.2.5 Western Europe Chemical Market, By Biotechnology
9.3.2.6 Western Europe Chemical Market, By Pharmacy and Retail
9.3.2.7 Western Europe Chemical Market, By Home Healthcare
9.3.2.8 Western Europe Chemical Market, By Diagnostics
9.3.2.9 Western Europe Chemical Market, By Health and Wellness
9.4 Asia-Pacific
9.4.1 Asia-Pacific Chemical Market, By Country
9.4.2 Asia-Pacific Chemical Market, By Pharmaceuticals
9.4.3 Asia-Pacific Chemical Market, By Healthcare Services
9.4.4 Asia-Pacific Chemical Market, By Medical Devices
9.4.5 Asia-Pacific Chemical Market, By Biotechnology
9.4.6 Asia-Pacific Chemical Market, By Pharmacy and Retail
9.4.7 Asia-Pacific Chemical Market, By Home Healthcare
9.4.8 Asia-Pacific Chemical Market, By Diagnostics
9.4.9 Asia-Pacific Chemical Market, By Health and Wellness
9.5 The Middle East & Africa
9.5.1 Middle East
9.5.1.1 Middle East Chemical Market, By Country
9.5.1.2 Middle East Chemical Market, By Pharmaceuticals
9.5.1.3 Middle East Chemical Market, By Healthcare Services
9.5.1.4 Middle East Chemical Market, By Medical Devices
9.5.1.5 Middle East Chemical Market, By Biotechnology
9.5.1.6 Middle East Chemical Market, By Pharmacy and Retail
9.5.1.7 Middle East Chemical Market, By Home Healthcare
9.5.1.8 Middle East Chemical Market, By Diagnostics
9.5.1.9 Middle East Chemical Market, By Health and Wellness
9.5.2 Africa
9.5.2.1 Africa Chemical Market, By Country
9.5.2.2 Africa Chemical Market, By Pharmaceuticals
9.5.2.3 Africa Chemical Market, By Healthcare Services
9.5.2.4 Africa Chemical Market, By Medical Devices
9.5.2.5 Africa Chemical Market, By Biotechnology
9.5.2.6 Africa Chemical Market, By Pharmacy and Retail
9.5.2.7 Africa Chemical Market, By Home Healthcare
9.5.2.8 Africa Chemical Market, By Diagnostics
9.5.2.8 Africa Chemical Market, By Health and Wellness
9.6 Latin America
9.6.1 Latin America Chemical Market, By Country
9.6.2 Latin America Chemical Market, By Pharmaceutical Chemicals
9.6.3 Latin America Chemical Market, By Healthcare Services
9.6.4 Latin America Chemical Market, By Medical Devices
9.6.5 Latin America Chemical Market, By Biotechnology
9.6.6 Latin America Chemical Market, By Pharmacy and Retail
9.6.7 Latin America Chemical Market, By Home Healthcare
9.6.8 Latin America Chemical Market, By Diagnostics
9.6.9 Latin America Chemical Market, By Health and Wellness

10 Company Profile of the Global Healthcare Market
10.1 Company Profile of Pharmaceuticals
10.1.1 Pfizer
10.1.1.1 Company Overview
10.1.1.2 Financials
10.1.1.3 Speed/Services/Offerings
10.1.1.4 SWOT Analysis
10.1.1.5 The SNS View
10.1.2 Novartis
10.1.3 Merck & Co.
10.1.4 Roche
10.1.5 GSK
10.1.6 Sanofi
10.1.7 Johnson & Johnson
10.1.8 AstraZeneca
10.1.9 AbbVie
10.1.10 Others
10.2 Company Profile of Healthcare Services
10.2.1 UnitedHealth Group
10.2.1.1 Company Overview
10.2.1.2 Financials
10.2.1.3 Speed/Services/Offerings
10.2.1.4 SWOT Analysis
10.2.1.5 The SNS View
10.2.2 Medtronic plc
10.2.3 GE HealthCare
10.2.4 McKesson
10.2.5 Abbott Laboratories
10.2.6 Johnson & Johnson
10.2.7 Philips
10.2.8 Pfizer
10.2.9 CVS Health Payor Solutions
10.2.10 Others
10.3 Company Profile of Medical Devices
10.3.1 Abbott
10.3.1.1 Company Overview
10.3.1.2 Financials
10.3.1.3 Speed/Services/Offerings
10.3.1.4 SWOT Analysis
10.3.1.5 The SNS View
10.3.2 Medtronic
10.3.3 Johnson & Johnson
10.3.4 Siemens Healthineers
10.3.5 Fresenius Medical Care
10.3.6 Becton Dickinson & Company
10.3.7 GE Healthcare
10.3.8 Stryker
10.3.9 Philips
10.3.10 Cardinal Health
10.4 Company Profile of Biotechnology
10.4.1 Eli Lilly
10.4.1.1 Company Overview
10.4.1.2 Financials
10.4.1.3 Speed/Services/Offerings
10.4.1.4 SWOT Analysis
10.4.1.5 The SNS View
10.4.2 Novo Nordisk
10.4.3 Johnson & Johnson
10.4.4 Merck
10.4.5 AbbVie
10.4.6 Roche
10.4.7 AstraZeneca
10.4.8 Novartis
10.4.9 Thermo Fisher Scientific
10.4.10 Amgen
10.5 Company Profile of Pharmacy and Retail
10.5.1 Cardinal Health, Inc
10.5.1.1 Company Overview
10.5.1.2 Financials
10.5.1.3 Speed/Services/Offerings
10.5.1.4 SWOT Analysis
10.5.1.5 The SNS View
10.5.2 Wal-Mart Stores, Inc.
10.5.3 McKesson Corporation
10.5.4 CVS Health Corporation
10.5.5 Walgreens Boots Alliance
10.6 Company Profile of Diagnostics
10.6.1 Thermo Fisher Scientific
10.6.1.1 Company Overview
10.6.1.2 Financials
10.6.1.3 Speed/Services/Offerings
10.6.1.4 SWOT Analysis
10.6.1.5 The SNS View
10.6.2 IDEXX Laboratories
10.6.3 SGS
10.6.4 Quest Diagnostics
10.6.5 Revvity
10.6.6 Exact Sciences
10.6.7 bioMérieux
10.6.8 Eurofins Scientific
10.6.9 Bruker
10.6.10 Sonic Healthcare
10.7 Company Profile of Health and Wellness
10.7.1 Amway Corporation
10.7.1.1 Company Overview
10.7.1.2 Financials
10.7.1.3 Speed/Services/Offerings
10.7.1.4 SWOT Analysis
10.7.1.5 The SNS View
10.7.2 Bayer AG
10.7.3 Danone S.A.
10.7.4 David Lloyd Leisure Ltd.
10.7.5 Curefit Healthcare Pvt. Ltd.
10.7.6 Herbalife International of America, Inc.
10.7.7 Letterone Investment Holdings S.A.
10.7.8 L’Oreal S.A.
10.7.9 Nestle S.A.
10.7.10 The Procter & Gamble Company

11. Competitive Landscape
11.1 Competitive Benchmarking
11.2 Market Share Analysis
11.3 Recent Developments
11.3.1 Industry News
11.3.2 Company News
11.3.3 Mergers & Acquisitions

12. USE Cases and Best Practices

13. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone